Effects of estradiol–drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women
- 201 Downloads
To investigate the effects of Angeliq on hormonal, metabolic, biochemical and cardiovascular profile, carotid intima-media thickness (CIMT) and vertigo/dizziness symptoms in postmenopausal women.
Angeliq is a drug used for hormone replacement therapy that composed of drospirenone 2 mg and estradiol 1 mg. Thirty-two postmenopausal women were recruited for the study. All women were evaluated using personal interview, medical examination and carotid artery ultrasound. They were questioned specifically about vertigo/dizziness experienced. Participants were randomly submitted to oral daily treatment with Angeliq. The duration of the study was 6 months and the participants were studied in basal condition and after 6 months of the therapy.
Follicle-stimulating hormone was significantly higher and estradiol was significantly lower in before therapy (BT) than in after therapy (AT) (p < 0.001). No differences in fasting glucose, CRP and WBC values, and lipid–lipoprotein profile were detected between the groups. The systolic and diastolic blood pressures and heart rate were also significantly higher in BT than in AT (p < 0.05). A significant (p < 0.001) difference in CIMT (0.51 ± 0.04 vs. 0.49 ± 0.03 mm) was found between BT and AT. Seven of 32 patients (22%) had vertigo/dizziness symptoms before treatment. After 6 months, none of the patients showed complaints of vertigo/dizziness.
Oral daily treatment with Angeliq reduces CIMT and climacteric complaints including vertigo/dizziness in postmenopausal women. They may relate to anti-androgenic and anti-mineralocorticoid effects of Angeliq, respectively.
KeywordsCardiovascular disease Carotid intima-media thickness Drospirenone Menopause Vertigo/dizziness
Body mass index
Coronary heart disease
Carotid intima-media thickness
Diastolic blood pressure
Hormone replacement therapy
Systolic blood pressure
White blood cells count
Conflict of interest statement
There is no conflict of interest between the authors.
- 5.Stevenson JC (2005) Menopausal hormone therapy. In: Wenger NK, Collins P (eds) Women and heart disease. Taylor and Francis, London, pp 375–390Google Scholar
- 21.Taskinen MR, Puolakka J, Pyorala T, Luotola H, Bjaorn M, Kaarianen J et al (1996) Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen_/progestin regimens. Arterioscler Thromb Vasc Biol 16:1215_/21Google Scholar
- 24.Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995) Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80:1816–1821PubMedCrossRefGoogle Scholar
- 32.Duvernoy CS, Rattenhuber J, Seifert-Klauss V, Bengel F, Meyer C, Schwaiger M (2001) Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women. J Gender Specific Med 4:21–27Google Scholar
- 40.Bonithon-Kopp C (1997) Prevalence of and risk factors for intimamedia thickening: a literature review. In: Touboul P-J, Crouse JR, (eds), Intima-media thickness and atherosclerosis: predicting the risk? Parthenon Publishing Group New York, NY, pp 27–44Google Scholar